期刊文献+

Viral hepatitis prevalence in patients with active and latent tuberculosis 被引量:7

Viral hepatitis prevalence in patients with active and latent tuberculosis
下载PDF
导出
摘要 AIM: To assess the prevalence of hepatitis B virus(HBV) and hepatitis C virus(HCV) infection and association with drug induced liver injury(DILI) in patients undergoing anti-tuberculosis(TB) therapy.METHODS: Four hundred and twenty nine patients with newly diagnosed TB- either active disease or latent infection- who were due to commence antiTB therapy between September 2008 and May 2011 were included. These patients were prospectively tested for serological markers of HBV, HCV and human immunodeficiency virus(HIV) infections- hepatitis B core antigen(HBc Ag), hepatitis B surface antigen(HBs Ag), hepatitis B e antigen, Ig G and Ig M antibody to HBc Ag(anti-HBc), HCV Ig G antibody and HIV antibody using a combination of enzyme-linked immunosorbent assay, Western blot assay and polymerase chain reaction techniques. Patients were reviewed at least monthly during the TB treatment initiation phase. Liver function tests were measured prior to commencement of antiTB therapy and 2-4 wk later. Liver function tests were also performed at any time the patient had significant nausea, vomiting, rash, or felt non-specifically unwell. Fisher's exact test was used to measure significance in comparisons of proportions between groups. A P value of less than 0.05 was considered statistically significant.RESULTS: Of the 429 patients, 270(62.9%) had active TB disease and 159(37.1%) had latent TB infection. 61(14.2%) patients had isolated anti-HBc positivity, 11(2.6%) were also HBs Ag positive and 7(1.6%) were HCV-antibody positive. 16/270 patients with active TB disease compared to 2/159 patients with latent TB infection had markers of chronic viral hepatitis(HBs Ag or HCV antibody positive; P = 0.023). Similarly the proportion of HBs Ag positive patients were significantly greater in the active vs latent TB infection group(10/43 vs 1/29, P = 0.04). The prevalence of chronic HBV or HCV was significantly higher than the estimated United Kingdom prevalence of 0.3% for each. We found no association between DILI and presence of serological markers of HBV or HCV. Three(5.3%) patients with serological markers of HBV or HCV infection had DILI compared to 25(9.5%) patients without; P = 0.04.CONCLUSION: Viral hepatitis screening should be considered in TB patients. DILI risk was not increased in patients with HBV/HCV. AIM: To assess the prevalence of hepatitis B virus(HBV) and hepatitis C virus(HCV) infection and association with drug induced liver injury(DILI) in patients undergoing anti-tuberculosis(TB) therapy.METHODS: Four hundred and twenty nine patients with newly diagnosed TB- either active disease or latent infection- who were due to commence antiTB therapy between September 2008 and May 2011 were included. These patients were prospectively tested for serological markers of HBV, HCV and human immunodeficiency virus(HIV) infections- hepatitis B core antigen(HBc Ag), hepatitis B surface antigen(HBs Ag), hepatitis B e antigen, Ig G and Ig M antibody to HBc Ag(anti-HBc), HCV Ig G antibody and HIV antibody using a combination of enzyme-linked immunosorbent assay, Western blot assay and polymerase chain reaction techniques. Patients were reviewed at least monthly during the TB treatment initiation phase. Liver function tests were measured prior to commencement of antiTB therapy and 2-4 wk later. Liver function tests were also performed at any time the patient had significant nausea, vomiting, rash, or felt non-specifically unwell. Fisher's exact test was used to measure significance in comparisons of proportions between groups. A P value of less than 0.05 was considered statistically significant.RESULTS: Of the 429 patients, 270(62.9%) had active TB disease and 159(37.1%) had latent TB infection. 61(14.2%) patients had isolated anti-HBc positivity, 11(2.6%) were also HBs Ag positive and 7(1.6%) were HCV-antibody positive. 16/270 patients with active TB disease compared to 2/159 patients with latent TB infection had markers of chronic viral hepatitis(HBs Ag or HCV antibody positive; P = 0.023). Similarly the proportion of HBs Ag positive patients were significantly greater in the active vs latent TB infection group(10/43 vs 1/29, P = 0.04). The prevalence of chronic HBV or HCV was significantly higher than the estimated United Kingdom prevalence of 0.3% for each. We found no association between DILI and presence of serological markers of HBV or HCV. Three(5.3%) patients with serological markers of HBV or HCV infection had DILI compared to 25(9.5%) patients without; P = 0.04.CONCLUSION: Viral hepatitis screening should be considered in TB patients. DILI risk was not increased in patients with HBV/HCV.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第29期8920-8926,共7页 世界胃肠病学杂志(英文版)
基金 Supported by Grants from the Wellcome Trust and the Higher Education Funding Council for England
关键词 EPIDEMIOLOGY HEPATITIS B HEPATITIS C TUBERCULOSIS Drug induced liver INJURY Epidemiology Hepatitis B Hepatitis C Tuberculosis Drug induced liver injury
  • 相关文献

参考文献2

二级参考文献81

  • 1LeiPan,Zhan-ShengJia,LinChen,En-QingFu,Guang-YuLi.Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus[J].World Journal of Gastroenterology,2005,11(16):2518-2521. 被引量:22
  • 2[1]Veiga-Fernandes H,Walter U,Bourgeois C,McLean A,Rocha B.Response of naive and memory CD8+ T cells to antigen stimulation in vivo.Nat Immunol 2000; 1:47-53
  • 3[2]Rocha B,Tanchot C.The Tower of Babel of CD8+ T-cell memory:known facts,deserted roads,muddy waters,and possible dead ends.Immunol Rev 2006; 211:182-196
  • 4[3]van Leeuwen EM,de Bree GJ,ten Berge IJ,van Lier RA.Human virus-specific CD8+ T cells:diversity specialists.Immunol Rev 2006; 211:225-235
  • 5[4]Kaech SM,Hemby S,Kersh E,Ahmed R.Molecular and functional profiling of memory CD8 T cell differentiation.Cell 2002; 111:837-851
  • 6[5]Kaech SM,Tan JT,Wherry EJ,Konieczny BT,Surh CD,Ahmed R.Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.Nat Immunol 2003; 4:1191-1198
  • 7[6]Oxenius A,Gunthard HF,Hirschel B,Fidler S,Weber JN,Easterbrook PJ,Bell JI,Phillips RE,Price DA.Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load.Eur J Immunol 2001; 31:1115-1121
  • 8[7]Fry TJ,Mackall CL.The many faces of IL-7:from lymphopoiesis to peripheral T cell maintenance.J Immunol 2005; 174:6571-6576
  • 9[8]Wolint P,Betts MR,Koup RA,Oxenius A.Immediate cytotoxicity but not degranulation distinguishes effector and memory subsets of CD8+ T cells.J Exp Med 2004; 199:925-936
  • 10[9]Huster KM,Busch V,Schiemann M,Linkemann K,Kerksiek KM,Wagner H,Busch DH.Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets.Proc Natl Acad Sci USA 2004; 101:5610-5615

共引文献17

同被引文献57

引证文献7

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部